113.55MMarket Cap-717P/E (TTM)
0.940High0.885Low640.69KVolume0.918Open0.890Pre Close582.18KTurnover0.56%Turnover RatioLossP/E (Static)124.62MShares1.95052wk High-0.67P/B104.53MFloat Cap0.61752wk Low--Dividend TTM114.72MShs Float49.005Historical High--Div YieldTTM6.18%Amplitude0.617Historical Low0.908Avg Price1Lot Size
Karyopharm Therapeutics Stock Forum
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet